SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 15, 2008
CardioVascular BioTherapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 000-51172 | 33-0795984 |
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
1635 Village Center Circle, Suite 250
Las Vegas, NV
(Address of Principal Executive Offices)
89134
(Zip Code)
Registrant’s telephone number, including area code: 702-839-7220
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01 Other Events
On April 1, 2008 CardioVascular BioTherapeutics, Inc. (the "Company") reported on Form 12b-25 that it could not file its annual Report on Form 10-K for the Company's fiscal year ended December 31, 2007 within the prescribed time period because the Company required additional time for compilation and review to insure adequate disclosure of certain information required to be included in the Form 10-K. In that Form 12b-25 the Company explained its Annual Report on Form 10-K would be filed on or before the fifteenth calendar day following the prescribed due date. As of the date of this Current Report on Form 8-K the Company nears completion of its compilation and review and anticipates filing its Annual Report on Form 10-K on or before Friday, April 18, 2008.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | |
| | CARDIOVASCULAR BIOTHERAPEUTICS, INC. |
|
|
|
| Date: April 15, 2008 | By: | /s/ Mickael A. Flaa |
| |
Mickael A. Flaa |
| | |
